AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2890671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31034014 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study 31034014 — intervention group
Group type: EXPERIMENTAL
Intervention: FV diet
Number of subjects: 459
Study 31034014 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 459
Study 28553091 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led education and mentorship program (n=53)
Number of subjects: 105
Study 28553091 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=52)
Number of subjects: 105
Study 27282118 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX only
Number of subjects: 0
Study 27282118 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX plus patient navigation (PN)
Number of subjects: 0
Study 27282118 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (ETAU)
Number of subjects: 0
Study 25128802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal FluMist seasonal influenza vaccine (3 doses on Days 0, 28, and 56) + rintatolimod (50 μg, 200 μg, or 500 μg)
Number of subjects: 12
Study 25128802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal FluMist seasonal influenza vaccine + rintatolimod
Number of subjects: 12
Study 21910949 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) 4 g in juice, consumed twice daily for 3 weeks
Number of subjects: 37
Study 21910949 — intervention group
Group type: COMPARATOR
Intervention: Placebo, consumed twice daily for 3 weeks
Number of subjects: 37
Study 19652172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene (136 households)
Number of subjects: 1201
Study 19652172 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical facemasks plus hand hygiene (137 households)
Number of subjects: 1201
Study 19652172 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education (control) (134 households)
Number of subjects: 1201
Study 17697173 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental resins (R1, R2, R3, R4, R5) applied to acid-etched dentine saturated with ethanol
Number of subjects: 0
Study 17697173 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental resins (R1, R2, R3, R4, R5) applied to acid-etched dentine saturated with water
Number of subjects: 0
Study 17697173 — intervention group
Group type: COMPARATOR
Intervention: Smear layer-covered dentine
Number of subjects: 0
Study 16055308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 500
Study 16055308 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 500
Study 16055308 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 500
Study 16055308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 500
Study 16055308 — intervention group
Group type: COMPARATOR
Intervention: Low dose of Haloperidol
Number of subjects: 500
Study 12109650 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Gammalinolenic acid (GLA) extracted from Evening Primrose Oil
Number of subjects: 90
Study 12109650 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 90
Study 12109650 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Gammalinolenic acid (GLA)
Number of subjects: 90
Study 10405233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1.0 g) with Lansoprazole (30 mg) after pretreatment with 30 mg once daily for 2 days
Number of subjects: 6
Study 10405233 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1.0 g) alone (control session)
Number of subjects: 6
Study 7486359 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg)
Number of subjects: 70
Study 7486359 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 70
Study 7486359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 70
Study 7486359 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 70
Study 7486359 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 70
Study 7486359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2123602 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravenous heparin anticoagulation (5,000 U bolus followed by 1,000 U/hour)
Number of subjects: 84
Study 2123602 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA alone
Number of subjects: 84
Study 7418403 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinesterol (long-acting estrogen)
Number of subjects: 214
Study 7418403 — intervention group
Group type: COMPARATOR
Intervention: Control (DMPA without quinesterol)
Number of subjects: 214
Study 31364228 — intervention group
Group type: EXPERIMENTAL
Intervention: OA-enriched olive oil (55 mL/day, equivalent to 30 mg OA/day)
Number of subjects: 176
Study 31364228 — intervention group
Group type: COMPARATOR
Intervention: Control group (same oil not enriched)
Number of subjects: 176
Study 31364228 — intervention group
Group type: EXPERIMENTAL
Intervention: OA-enriched olive oil
Number of subjects: 176
Study 28401134 — intervention group
Group type: EXPERIMENTAL
Intervention: iCCAS
Number of subjects: 148
Study 28401134 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 25869753 — intervention group
Group type: COMPARATOR
Intervention: DDDR (n = 385)
Number of subjects: 1166
Study 25869753 — intervention group
Group type: COMPARATOR
Intervention: MVP (n = 398)
Number of subjects: 1166
Study 25869753 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDRP+MVP (n = 383)
Number of subjects: 1166
Study 25869753 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive ATP efficacy
Number of subjects: 1166
Study 23509827 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training
Number of subjects: 28
Study 23509827 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness training
Number of subjects: 28
Study 23509827 — intervention group
Group type: COMPARATOR
Intervention: Reference intervention
Number of subjects: 28
Study 23509827 — intervention group
Group type: COMPARATOR
Intervention: Repetitive stressful work
Number of subjects: 28
Study 21214497 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband light (400-800 nm) at 180 mW/cm², twice a day for 4 min/session
Number of subjects: 16
Study 21214497 — intervention group
Group type: COMPARATOR
Intervention: Placebo light (10 mW/cm²)
Number of subjects: 16
Study 21214497 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband light (400-800 nm)
Number of subjects: 16
Study 19957880 — intervention group
Group type: EXPERIMENTAL
Intervention: Response format: true‐false
Number of subjects: 0
Study 19957880 — intervention group
Group type: EXPERIMENTAL
Intervention: Response format: agree‐disagree
Number of subjects: 0
Study 19957880 — intervention group
Group type: EXPERIMENTAL
Intervention: Response format: yes‐no
Number of subjects: 0
Study 19957880 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing of items around freedom given responsibility
Number of subjects: 0
Study 19957880 — intervention group
Group type: COMPARATOR
Intervention: Framing of items around responsibility given freedom
Number of subjects: 0
Study 17926613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with 'Hongwai Zhike Plaster' at Dazhui (GV 14), Dingchuan (EX‐B 1), Tiantu (CV 22) plus common treatment.
Number of subjects: 300
Study 17926613 — intervention group
Group type: COMPARATOR
Intervention: Common treatment (giving up smoking, proper exercise).
Number of subjects: 300
Study 17926613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy.
Number of subjects: 300
Study 15569129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg b.i.d.)
Number of subjects: 44
Study 15569129 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1 g b.i.d.)
Number of subjects: 44
Study 15569129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12882461 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 14
Study 12882461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9639502 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral T-cell lymphomas (PTCL)
Number of subjects: 1883
Study 9639502 — intervention group
Group type: COMPARATOR
Intervention: B-cell lymphomas (BCL)
Number of subjects: 1883
Study 9639502 — intervention group
Group type: EXPERIMENTAL
Intervention: T-ALCL (anaplastic large cell lymphoma)
Number of subjects: 1883
Study 8194130 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine treatment
Number of subjects: 0
Study 8194130 — intervention group
Group type: COMPARATOR
Intervention: Plasma from HIV-infected patients
Number of subjects: 0
Study 8194130 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected patients
Number of subjects: 0
Study 2695415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor, 40 mg/kg/day in 3 divided doses for 10 days
Number of subjects: 86
Study 2695415 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX), 1 mg/kg/day (trimethoprim 8 mg, sulfamethoxazole 40 mg) in 2 divided doses for 10 days
Number of subjects: 86
Study 321094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxytetracycline (250 mg twice a day)
Number of subjects: 400
Study 321094 — intervention group
Group type: COMPARATOR
Intervention: Triple tetracycline
Number of subjects: 400
Study 321094 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release tetracycline hydrochloride
Number of subjects: 400
Study 321094 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment of asymptomatic contacts
Number of subjects: 400
Study 31149991 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoMed
Number of subjects: 520
Study 31149991 — intervention group
Group type: COMPARATOR
Intervention: Orsiro
Number of subjects: 520
Study 28438152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group A (trained and delivered the intervention at baseline)
Number of subjects: 1263
Study 28438152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group B (training and delivery 3 months later)
Number of subjects: 1263
Study 28438152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (community pharmacist-led Medicines Use Review)
Number of subjects: 1263
Study 25747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (RT)
Number of subjects: 97
Study 25747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with protein and vitamin supplementation (RTS)
Number of subjects: 97
Study 25747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT)
Number of subjects: 97
Study 22741052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg orally, given 6 hours before and 6 to 12 hours after surgery
Number of subjects: 80
Study 22741052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group), given 6 hours before and 6 to 12 hours after surgery
Number of subjects: 80
Study 19399753 — intervention group
Group type: EXPERIMENTAL
Intervention: New intervention (not specified)
Number of subjects: 0
Study 19399753 — intervention group
Group type: EXPERIMENTAL
Intervention: Value of information methods
Number of subjects: 0
Study 19399753 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies (not specified)
Number of subjects: 0
Study 18483353 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention of standardized materials in the public domain
Number of subjects: 543
Study 16418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Versed + Fentanyl
Number of subjects: 100
Study 16418586 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study 12790360 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy
Number of subjects: 26
Study 12790360 — intervention group
Group type: COMPARATOR
Intervention: ACS
Number of subjects: 26
Study 10228254 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1 mg/mL)
Number of subjects: 60
Study 10228254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10228254 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 60
Study 8734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 0.25 g/day and aspirin 0.10 g/day for one month with low molecular weight heparin
Number of subjects: 1294
Study 8734180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low incidence of subocclusion after coronary stenting
Number of subjects: 1294
Study 1915909 — intervention group
Group type: EXPERIMENTAL
Intervention: HUV
Number of subjects: 191
Study 1915909 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 191
Study 6343750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (preoperative gamma-therapy with doses of 4-5 Gy up to 20-25 Gy or 10 Gy up to 50 Gy)
Number of subjects: 154
Study 6343750 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone
Number of subjects: 154
Study 30240024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mL intra-articular injection)
Number of subjects: 54
Study 30240024 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 mL intra-articular injection)
Number of subjects: 54
Study 30240024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 54
Study 29161530 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered breastfeeding education program (two prenatal lectures, three home visits, eight telephone calls, text/video/audio support, quality online resources)
Number of subjects: 59
Study 29161530 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered breastfeeding education program
Number of subjects: 59
Study 29161530 — intervention group
Group type: COMPARATOR
Intervention: In-hospital care and follow-up by community nurses
Number of subjects: 59
Study 27693898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet (FBT)
Number of subjects: 10
Study 27693898 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine
Number of subjects: 10
Study 27693898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet (FBT) and Immediate-release morphine
Number of subjects: 10
Study 23594026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich bone augmentation with a bovine pericardium membrane
Number of subjects: 26
Study 23594026 — intervention group
Group type: COMPARATOR
Intervention: No membrane (control group)
Number of subjects: 26
Study 22222005 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy (5,000 IU subcutaneously at 48 h and 72 h after IS)
Number of subjects: 160
Study 22222005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 22222005 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP levels at 48 h and day 21 after IS
Number of subjects: 160
Study 19559369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative navigation
Number of subjects: 20
Study 19559369 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative navigation (Control)
Number of subjects: 20
Study 17727352 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed diary assessing number of satisfactory sexual events (SSEs) per week
Number of subjects: 865
Study 17727352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 16407341 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0
Study 16407341 — intervention group
Group type: COMPARATOR
Intervention: Quinine-doxycycline
Number of subjects: 0
Study 16407341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 14998223 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 0
Study 14998223 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietic agents
Number of subjects: 0
Study 14998223 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-conservation tools and minimization of phlebotomy
Number of subjects: 0
Study 14998223 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational oxygen-carrying agents
Number of subjects: 0
Study 11035671 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-CPAP (pressure range 6 to 16 cm H(2)O)
Number of subjects: 25
Study 11035671 — intervention group
Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 25
Study 8832540 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 15
Study 8832540 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 1575180 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress monitoring and intervention (home nursing visits for high stress symptoms)
Number of subjects: 461
Study 1575180 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 461
Study 4049902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg loprazolam
Number of subjects: 6
Study 4049902 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg loprazolam
Number of subjects: 6
Study 4049902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31852704 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised package of interventions for TB treatment adherence
Number of subjects: 0
Study 28720615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 290
Study 28720615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 25963890 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF with RBV
Number of subjects: 1952
Study 25963890 — intervention group
Group type: COMPARATOR
Intervention: LDV/SOF without RBV
Number of subjects: 1952
Study 23565760 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg once daily)
Number of subjects: 618
Study 23565760 — intervention group
Group type: COMPARATOR
Intervention: Metformin (up to 2250 mg/day)
Number of subjects: 618
Study 21342151 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 2.5 mg/kg
Number of subjects: 78
Study 21342151 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.0 mg/kg
Number of subjects: 78
Study 20467604 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin orally 1 hour before implant placement
Number of subjects: 105
Study 20467604 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablets
Number of subjects: 105
Study 17367893 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg controlled-release doxycycline once daily
Number of subjects: 537
Study 17367893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 15481334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg/6 hr during 3 days)
Number of subjects: 24
Study 15481334 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen-arginate (600 mg/6 hr during 3 days)
Number of subjects: 24
Study 15481334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 24
Study 15481334 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen-arginate
Number of subjects: 24
Study 15481334 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and ibuprofen-arginate
Number of subjects: 24
Study 11560082 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg.kg‐1
Number of subjects: 12
Study 11560082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 11560082 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 12
Study 9627589 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms
Number of subjects: 404
Study 9627589 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms
Number of subjects: 404
Study 9627589 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 404
Study 9627589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 8176099 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 41
Study 8176099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3666158 — intervention group
Group type: EXPERIMENTAL
Intervention: Human alpha interferon 3 x 10(6) units subcutaneously daily for 1 year
Number of subjects: 32
Study 3666158 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 32
Study 31243447 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted BMI
Number of subjects: 228951
Study 31243447 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted breast size
Number of subjects: 228951
Study 28438377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DSM9843 (LP299V)
Number of subjects: 438
Study 28438377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 25559009 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond diet (1.5 oz. of almonds/day)
Number of subjects: 48
Study 25559009 — intervention group
Group type: COMPARATOR
Intervention: Control diet (isocaloric muffin substitution)
Number of subjects: 48
Study 23208198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive rotigotine (≤16 mg/24 h)
Number of subjects: 653
Study 21911107 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (0.25 to 10 mg)
Number of subjects: 64
Study 21911107 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.25 to 4 mg)
Number of subjects: 64
Study 21911107 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (1.25 to 20 mg)
Number of subjects: 64
Study 19186725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment
Number of subjects: 0
Study 16322100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural alcohol program (CBAP)
Number of subjects: 177
Study 16322100 — intervention group
Group type: COMPARATOR
Intervention: Post-mailed minimal intervention (PMMI)
Number of subjects: 177
Study 15229466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg twice daily for 11 days)
Number of subjects: 12